Yukmijihwang-tang inhibits receptor activator for nuclear factor-κB ligand-induced osteoclast differentiation

Journal of Medicinal Food

Volumn 14, Issue 11, 2011, Pages 1439-1447

  Shim, Ki Shuk ^a   Ma, Choong Je ^b   Kim, Dong Seon ^a   Ma, Jin Yeul ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

osteoclast differentiation; RAW264.7 cells; receptor activator for nuclear factor jB ligand; Yukmijihwang tang

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; GELATINASE B; HERBACEOUS AGENT; I KAPPA B KINASE ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; YUKMIJIHWANG TANG;

ARTICLE; CELL PROLIFERATION; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACID PHOSPHATASE; ANIMALS; BONE RESORPTION; CATHEPSIN K; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; I-KAPPA B PROTEINS; ISOENZYMES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIGANDS; MATRIX METALLOPROTEINASE 9; MICE; NF-KAPPA B; OSTEOCLASTS; PHOSPHORYLATION; RANK LIGAND; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 80755130551     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2010.1502     Document Type: Article

References (47)

1. Teitelbaum SL: Bone resorption by osteoclasts. Science 2000;289:1504-1508.
2. Rodan GA, Martin TJ: Therapeutic approaches to bone diseases. Science 2000;289:1508-1514.
3. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357. (Pubitemid 30649812)
4. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 2003;423:337-342. (Pubitemid 40852708)
5. Putnam SE, Scutt AM, Bicknell K, Priestley CM, Williamson EM: Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health. Phytother Res 2007;21:99-112.
6. Rho S, Kang M, Choi B, Sim D, Lee J, Lee E, Cho C, Oh JW, Park S, Ko S, Shin M, Hong M, Bae H: Effects of Yukmijihwang-tang derivatives (YMJd), a memory enhancing herbal extract, on the gene-expression profile in the rat hippocampus. Biol Pharm Bull 2005;28:87-93. (Pubitemid 40879789)
7. KangM, KimJH, Cho C, Lee KY, ShinM, HongM, ShimI, Bae H: Effects ofYukmijihwang-tang derivatives (YMJd) on ibotenic acidinduced amnesia in the rat. Biol Pharm Bull 2006;29:1431-1435.
8. Oh MS, Chang MS, Park W, Kim DR, Bae H, Huh Y, Park SK: Yukmijihwang-tang protects against cyclophosphamide-induced reproductive toxicity. Reprod Toxicol 2007;24:365-370. (Pubitemid 350016758)
9. Kang DG, Sohn EJ, Moon MK, Mun YJ, Woo WH, Kim MK, Lee HS: Yukmijihwang-tang ameliorates ischemia/reperfusioninduced renal injury in rats. J Ethnopharmacol 2006;104:47-53. (Pubitemid 43234081)
10. Kim JS, Na CS, Pak SC, Kim YG: Effects of yukmi, an herbal formula, on the liver of senescence accelerated mice (SAM) exposed to oxidative stress. Am J Chin Med 2000;28:343-350.
11. Jin UH, Kim DI, Lee TK, Lee DN, Kim JK, Lee IS, Kim CH: Herbal formulation: Yukmi-jihang-tang-Jahage, regulates bone resorption by inhibition of phosphorylation mediated by tyrosine kinase Src and cyclooxygenase expression. J Ethnopharmacol 2006;106:333-343.
12. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan EL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-3545. (Pubitemid 29168945)
13. Battaglino R, Kim D, Fu J, Vaage B, Fu XY, Stashenko P: c-myc is required for osteoclast differentiation. J Bone Miner Res 2002;17:763-773. (Pubitemid 34441892)
14. Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, Yoshida N, Nakayama K: U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 2002;277:47366-47372. (Pubitemid 36159251)
15. Takayanagi H: Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292-304. (Pubitemid 46480961)
16. Kim MH, Shim KS, Kim SH: Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption. Arch Pharm Res 2010;33:457-462.
17. Rozen S, Skaletsky HJ: Primer3 on theWWWfor general users and for biologist programmers. Methods Mol Biol 2000;132:365-386.
18. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCT method. Methods 2001;25:402-408. (Pubitemid 34164012)
19. Won JB, Ma JY, Ma CJ: Simultaneous determination of four marker components in Yukmijihwang Tang by high performance liquid chromatography/diode array detector. Arch Pharm Res 2010;33:619-623.
20. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y: The TRAF family of signal transducers mediates NF-jB activation by the TRANCE receptor. J Biol Chem 1998;273: 28355-28359. (Pubitemid 28496137)
21. Kim HH, Lee DE, Shin JN, Lee YS, Jeon YM, Chung CH, Ni J, Kwon BS, Lee ZH: Receptor activator of NF-jB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 1999;443:297-302. (Pubitemid 29080814)
22. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M: Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-jB ligand (RANKL). J Biol Chem 2000;275:31155-31161.
23. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901. (Pubitemid 35460788)
24. Srivastava S, Weitzmann MN, Cenci S, Ross FP, Adler S, Pacifici R: Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest 1999;104:503-513. (Pubitemid 29534334)
25. Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH: Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun 2006;351:99-105. (Pubitemid 44635412)
26. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E, Takayanagi H: Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202: 1261-1269. (Pubitemid 41586956)
27. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T: Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004;114:475-484. (Pubitemid 39572097)
28. Wang ZQ, Ovitt C, Grigoriadis AE, Möhle-Steinlein U, Rüther U, Wagner EF: Bone and haematopoietic defects in mice lacking c-fos. Nature 1992;6406:741-745. (Pubitemid 23012271)
29. Huang H, Ryu J, Ha J, Chang EJ, Kim HJ, Kim HM, Kitamura T, Lee ZH, Kim HH: Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-jB transactivation by RANKL. Cell Death Differ 2006;13:1879-1891. (Pubitemid 44542401)
30. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, Hisatake K, Nogi Y: Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004;279:45969-45979. (Pubitemid 39491590)
31. Hogan PG, Chen L, Nardone J, Rao A: Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003;17:2205-2232. (Pubitemid 37128637)
32. Fleischmann A, Hafezi F, Elliott C, Remé CE, Rüther U, Wagner EF: Fra-1 replaces c-Fos-dependent functions in mice. Genes Dev 2000;14:2695-2700. (Pubitemid 32531196)
33. Kameda T, Akahori A, Sonobe MH, Suzuki T, Endo T, Iba H: JunD mutants with spontaneously acquired transforming potential have enhanced transactivating activity in combination with Fra-2. Proc Natl Acad Sci U S A 1993;90:9369-9373. (Pubitemid 23315785)
34. Soysa NS, Alles N: NF-jB functions in osteoclasts. Biochem Biophys Res Commun 2009;378:1-5.
35. Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K: Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-κB inhibitor, through downregulation of NFATc1. J Bone Miner Res 2005;20:653-662. (Pubitemid 40393074)
36. Dong J, Jimi E, Zhong H, Hayden MS, Ghosh S: Repression of gene expression by unphosphorylated NF-jB p65 through epigenetic mechanisms. Genes Dev 2008;22:1159-1173. (Pubitemid 351656576)
37. Reddy SV, Hundley JE, Windle JJ, Alcantara O, Linn R, Leach RJ, Boldt DH, Roodman GD: Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter. J Bone Miner Res 1995;10:601-606.
38. Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ, Fisher DE: Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci U S A 2001;98:5798-5803. (Pubitemid 32435722)
39. Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N: Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett 2009;583:2435-2440.
40. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV: RANK ligand signaling modulates the matrix metalloproteinase- 9 gene expression during osteoclast differentiation. Exp Cell Res 2007;313:168-178. (Pubitemid 44958461)
41. Pang M, Martinez AF, Fernandez I, Balkan W, Troen BR: AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells. Gene 2007;15:151-158. (Pubitemid 47488713)
42. Halleen JM, Räisänen S, Salo JJ, Reddy SV, Roodman GD, Hentunen TA, Lehenkari PP, Kaija H, Vihko P, Väänänen HK: Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1999;274:22907-22910.
43. Saftig P, Hunziker E, Everts V, Jones S, Boyde A, Wehmeyer O, Suter A, von Figura K: Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. Adv Exp Med Biol 2000;477:293-303.
44. Ishibashi O, Niwa S, Kadoyama K, Inui T: MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sci 2006; 79:1657-1660. (Pubitemid 44344731)
45. Wu H, Xu G, Li YP: ATP6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J Bone Miner Res 2009;24:871-885.
46. Yin J, Han N, Liu Z, Xu X, Zhang B, Kadota S: The in vitro antiosteoporotic activity of some diarylheptanoids and lignans from the rhizomes of Dioscorea spongiosa. Planta Med 2008;74: 1451-1453.
47. Jeong JC, Kang SK, Youn CH, Jeong CW, Kim HM, Lee YC, Chang YC, Kim CH: Inhibition of Drynariae Rhizoma extracts on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts. Int Immunopharmacol 2003;3:1685-1697.